人体肝细胞中药物诱导的调节元件会影响与不良反应相关的分子表型
Saki Gotoh-Saito1, Ryoko Wada1, Tomoe Nishimura2
1Research Center for Genome & Medical Sciences, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
Nature communications
|April 29, 2025
概括
这项研究揭示了非编码基因变异如何通过识别受孕前X受体 (PXR) 影响的调节元件来影响药物反应. 这些发现为药物不良反应和个性化医疗提供了新的见解.
科学领域:
- 基因组学就是基因组学.
- 药物基因组学 药物基因组学
- 分子生物学分子生物学
背景情况:
- 对药物反应的编码多态度得到了很好的研究,但对非编码调节元素的探索不足.
- 药物疗效和不良反应的个体差异是由基因组变异驱动的.
- 孕妇X受体 (PXR) 是药物代谢和反应的关键调节者.
研究的目的:
- 识别和描述在药物反应中活跃的非编码 cis调节元件 (CREs).
- 研究PXR在调节这些CREs中的作用.
- 发现影响药物反应和代谢途径的非编码变体.
主要方法:
- 利用基因表达的CAP分析 (CAGE) 来分析mRNA和增强RNA转录.
- 在表达PXR的HepG2细胞中评估CRE活性.
- 综合数据与全基因组关联研究 (GWAS) 和来自初级肝细胞的PXR结合数据.
主要成果:
- 鉴定了药物诱导的CRE,与胆红素和维生素D水平相关的变异相近.
- 发现了对UGT1A1,TSKU和CYP24A1的PXR结合增强剂,包括改变调控活性的功能性基.
- 发现TSKU影响维生素D代谢酶.
结论:
- 扩大了已知的PXR介导的监管元素的范围.
- 发现了影响药物反应的非编码变体,为药物不良反应提供了洞察力.
- 突出了非编码变异在个性化药物反应和代谢调节中的作用.
相关概念视频
Cis-regulatory Sequences
9.5K
Cis-regulatory sequences are short fragments of non-coding DNA that are present on the same chromosomes as the genes that they regulate. These fragments serve as binding sites for transcriptional regulators, proteins that are responsible for controlling gene transcription and differential gene expression across cell types in eukaryotes. Cis-regulatory sequences can be close to the gene of interest or thousands of bases away in the DNA sequence; however, those sequences that are further away are...
9.5K
Cell Specific Gene Expression
13.3K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.3K
Transducer Mechanism: Nuclear Receptors
1.2K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.2K
Epigenetic Regulation
2.9K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
2.9K
Co-activators and Co-repressors
7.1K
Gene transcription is regulated by the synergistic action of several proteins that form a complex at a gene regulatory site. This is observed in eukaryotes, where the regulation of gene expression is a complex process. Regulatory proteins in eukaryotes can broadly be classified into two types – regulators that bind directly to specific DNA sequences and co-regulators that associate with regulatory proteins but cannot directly bind to the DNA. These co-regulators are further divided into...
7.1K
Mutagenicity and Carcinogenicity
1.1K
Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
1.1K


